Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Heyward

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 23, 2025
Association Between Metformin Use and Mortality Among Individuals With Non-Small Cell Lung Cancer Receiving Immune Checkpoint Inhibitors: A Retrospective Cohort StudyXinyi Sun, James Heyward, Joseph C Murray, et al.
JAMA|February 20, 2019
Assessment of the FDA Risk Evaluation and Mitigation Strategy for Transmucosal Immediate-Release Fentanyl ProductsJeffrey Eric Rollman, James Heyward, Lily Olson, et al.
JAMA Oncology|May 8, 2025
Harm-Benefit Balance of Immune Checkpoint Inhibitors in Non-Small Cell Lung CancerJames Heyward, Catherine R Lesko, Joseph C Murray, et al.
Annals of Internal Medicine|September 28, 2020
Key Evidence Supporting Prescription Opioids Approved by the U.S. Food and Drug Administration, 1997 to 2018James Heyward, Thomas J Moore, Jennifer Chen, et al.
JAMA Network Open|October 2, 2020
Use and Content of Primary Care Office-Based vs Telemedicine Care Visits During the COVID-19 Pandemic in the USG Caleb Alexander, Matthew Tajanlangit, James Heyward, et al.
Drug and Alcohol Dependence|June 27, 2021
Primary care physicians' preparedness to treat opioid use disorder in the United States: A cross-sectional surveyKathryn Foti, James Heyward, Matthew Tajanlangit, et al.
JAMA Internal Medicine|December 31, 2019
Evaluation of the Extended-Release/Long-Acting Opioid Prescribing Risk Evaluation and Mitigation Strategy Program by the US Food and Drug Administration: A ReviewJames Heyward, Lily Olson, Joshua M Sharfstein, et al.
Diabetes, Obesity & Metabolism|April 21, 2021
Ambulatory noninsulin treatment of type 2 diabetes mellitus in the United States, 2015 to 2019James Heyward, Jacob Christopher, Sudipa Sarkar, et al.
Ophthalmology. Retina|July 19, 2017
Setting Priorities for Diabetic Retinopathy Clinical Research and Identifying Evidence GapsJimmy T Le, Susan Hutfless, Tianjing Li, et al.
Journal of the American Heart Association|April 27, 2022
National Trends in Use of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists by Cardiologists and Other Specialties, 2015 to 2020Rishav Adhikari, Kunal Jha, Zeina Dardari, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Journal of Immunotherapy (Hagerstown, Md. : 1997)|June 23, 2025
Association Between Metformin Use and Mortality Among Individuals With Non-Small Cell Lung Cancer Receiving Immune Checkpoint Inhibitors: A Retrospective Cohort StudyXinyi Sun, James Heyward, Joseph C Murray, et al.
JAMA|February 20, 2019
Assessment of the FDA Risk Evaluation and Mitigation Strategy for Transmucosal Immediate-Release Fentanyl ProductsJeffrey Eric Rollman, James Heyward, Lily Olson, et al.
JAMA Oncology|May 8, 2025
Harm-Benefit Balance of Immune Checkpoint Inhibitors in Non-Small Cell Lung CancerJames Heyward, Catherine R Lesko, Joseph C Murray, et al.
Annals of Internal Medicine|September 28, 2020
Key Evidence Supporting Prescription Opioids Approved by the U.S. Food and Drug Administration, 1997 to 2018James Heyward, Thomas J Moore, Jennifer Chen, et al.
JAMA Network Open|October 2, 2020
Use and Content of Primary Care Office-Based vs Telemedicine Care Visits During the COVID-19 Pandemic in the USG Caleb Alexander, Matthew Tajanlangit, James Heyward, et al.
Drug and Alcohol Dependence|June 27, 2021
Primary care physicians' preparedness to treat opioid use disorder in the United States: A cross-sectional surveyKathryn Foti, James Heyward, Matthew Tajanlangit, et al.
JAMA Internal Medicine|December 31, 2019
Evaluation of the Extended-Release/Long-Acting Opioid Prescribing Risk Evaluation and Mitigation Strategy Program by the US Food and Drug Administration: A ReviewJames Heyward, Lily Olson, Joshua M Sharfstein, et al.
Diabetes, Obesity & Metabolism|April 21, 2021
Ambulatory noninsulin treatment of type 2 diabetes mellitus in the United States, 2015 to 2019James Heyward, Jacob Christopher, Sudipa Sarkar, et al.
Ophthalmology. Retina|July 19, 2017
Setting Priorities for Diabetic Retinopathy Clinical Research and Identifying Evidence GapsJimmy T Le, Susan Hutfless, Tianjing Li, et al.
Journal of the American Heart Association|April 27, 2022
National Trends in Use of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists by Cardiologists and Other Specialties, 2015 to 2020Rishav Adhikari, Kunal Jha, Zeina Dardari, et al.
Pageof 3